This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/038239-2025

Not applicable

Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

NHS England

F14: Notice for changes or additional information

Notice identifier: 2025/S 000-038239

Procurement identifier (OCID): ocds-h6vhtk-0515a8

Published 8 July 2025, 1:43pm

Section I: Contracting authority/entity

I.1) Name and addresses

NHS England

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

Contact

Jessica Gaucher-Thompson

Email

jessica.gaucher-thompson@nhs.net

Country

United Kingdom

Region code

UKJ1 - Berkshire, Buckinghamshire and Oxfordshire

Internet address(es)

Main address

https://www.england.nhs.uk/

Buyer's address

https://www.england.nhs.uk/

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

II.1.2) Main CPV code

• 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).

The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Section VI. Complementary information

VI.6) Original notice reference

Notice number: 2025/S 000-022156

Section VII. Changes

VII.1.2) Text to be corrected in the original notice

Section number

11.1.4.1

Instead of

Text

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years). The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Read

Text

NHS England has taken the decision to abandon this competitive provider selection process (effective from 30th June 2025) for lifileucel, a cellular therapy for previously treated unresectable or metastatic melanoma (NICE ID 3863). NHS England remains committed to commissioning this service, as this tumour infiltrating lymphocyte cell therapy progresses through the NICE TA process, in line with the relevant procurement regulations and intends to progress this at the earliest suitable opportunity. Any future opportunities will be advertised in line with these the relevant procurement regulations, for example via the Find a Tender Service, and we will also notify all providers registered against the current process. This is a Provider Selection Regime (PSR) notice that this provider selection process has been abandoned and a contract has not been awarded. This process has been abandoned under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.